公开(公告)号：US20120064007A1

公开(公告)日：2012-03-15

申请号：US13299969

申请日：2011-11-18

申请人： Andrew R. Blight ,  Lawrence Maranucci ,  Ron Cohen

发明人： Andrew R. Blight ,  Lawrence Maranucci ,  Ron Cohen

IPC分类号： A61K49/00 ,  A61P25/00 ,  A61K31/4409

CPC分类号： A61K31/4409 ,  A61K9/20 ,  A61K31/435 ,  A61K31/44

摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

公开(公告)号：US20120164078A1

公开(公告)日：2012-06-28

申请号：US13410388

申请日：2012-03-02

申请人： Andrew R. Blight ,  Lawrence Maranucci ,  Ron Cohen

发明人： Andrew R. Blight ,  Lawrence Maranucci ,  Ron Cohen

IPC分类号： A61K49/00 ,  A61P25/00 ,  A61P21/00 ,  A61K31/4409

CPC分类号： A61K31/4409 ,  A61K9/20 ,  A61K31/435 ,  A61K31/44

摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

摘要翻译： 一种药物组合物，其包含分散在释放基质中的治疗有效量的氨基吡啶，包括例如可以配制成稳定的持续释放口服剂量制剂的组合物，例如在给药至 患者，氨基吡啶的治疗有效血浆水平约12小时，以及使用该组合物治疗各种神经疾病，包括多发性硬化。 基于对治疗的反应性来选择个体的方法，包括例如鉴定用持续释放的芬太尼组合物治疗反应的个体。

公开(公告)号：US20050228030A1

公开(公告)日：2005-10-13

申请号：US11102559

申请日：2005-04-08

申请人： Andrew Blight ,  Lawrence Maranucci ,  Ron Cohen

发明人： Andrew Blight ,  Lawrence Maranucci ,  Ron Cohen

IPC分类号： A61K31/44

CPC分类号： A61K31/4409 ,  A61K9/20 ,  A61K31/435 ,  A61K31/44

摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

摘要翻译： 一种药物组合物，其包含分散在释放基质中的治疗有效量的氨基吡啶，包括例如可以配制成稳定的持续释放口服剂量制剂的组合物，例如在给药至 患者，氨基吡啶的治疗有效血浆水平约12小时，以及使用该组合物治疗各种神经疾病，包括多发性硬化。 基于对治疗的反应性来选择个体的方法，包括例如鉴定用持续释放的芬太尼组合物治疗反应的个体。